Aurpibul L, et al. - A multisite cross-sectional study was conducted to ascertain hepatitis B (HBV) seroprevalence in children and adolescents participating in the TREAT Asia Pediatric HIV Observational Database. Study participants were HIV-infected patients currently <25 years old receiving antiretroviral treatment (ART) who had HBV surface antigen (HBsAg), or HBV surface antibody (anti-HBs) or HBV core antibody (anti-HBc) tested during 2012–2013. It was observed that the estimated prevalence of HBV coinfection in this cohort of Asian HIV-infected children and adolescents on ART was 5.2%. Researchers found that the majority of children and adolescents tested in this cohort (76.5%) did not have protective HBV antibody. They recommended HBV screening of HIV-infected children and adolescents to guide revaccination, the use of ART with anti-HBV activity and future monitoring.